- cafead Sep 06, 2024 at 10:52: AM
via Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment for geographic atrophy (GA).
BI 771716 is an investigational antibody fragment created to preserve vision in individuals with GA, a severe form of late-stage dry age-related macular degeneration (AMD).
article source
BI 771716 is an investigational antibody fragment created to preserve vision in individuals with GA, a severe form of late-stage dry age-related macular degeneration (AMD).
article source